3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
20
Neoplasm Metastasis
4
Neoplasms
3
Melanoma
3
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thrombosis
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Immune System Diseases
1
Hormone Receptor Positive Advanced Breast Cancer
1
Head and Neck Neoplasms
1
HER2+ Breast Cancer
1
Gastrointestinal Neoplasms
1
Estrogen Receptor-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
ER Positive, HER2 Negative Breast Cancer
1
Colonic Neoplasms
1
Chordoma
1
Cardiovascular Diseases
1
Interventions
Methotrexate
5
Drug Therapy
5
apatinib
4
Neoadjuvant Therapy
4
Doxorubicin
3
camrelizumab
2
Ifosfamide
2
Cisplatin
2
trilaciclib
1
spartalizumab
1
palbociclib
1
isophosphamide mustard
1
irinotecan sucrosofate
1
glucarpidase
1
endostar protein
1
Zoledronic Acid
1
Vinorelbine
1
Triptorelin Pamoate
1
Trabectedin
1
Therapeutics
1
Thalidomide
1
TQ-B3525
1
Psychiatric Rehabilitation
1
Nivolumab
1
Neuropsychological Tests
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Microbiota
1
Metabolome
1
Magnetic Resonance Spectroscopy
1
Lithium Carbonate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Osteosarcoma
×
palbociclib
×
Clear all
NCT03242382
2024-01-23
PalboSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Unknown
40 enrolled